Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202213 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT02202213 is a Phase 1 study of Schizophrenia that has completed, run by H. Lundbeck A/S. The registered enrollment target is 47 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02202213, a Phase 1 study of Schizophrenia, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Lu AF11167
Study Locations (1)
California
- Parexel International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202213
The ClinicalTrials.gov registry entry for NCT02202213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower). The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02202213 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02202213 about?
NCT02202213 is a clinical study titled "Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia". The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
What is the current status of trial NCT02202213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2013-10.
What conditions does trial NCT02202213 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT02202213?
The interventions under investigation include: Placebo (DRUG), Lu AF11167 (DRUG).
Who is sponsoring clinical trial NCT02202213?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202213 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.